Novartis Says Sandoz Biosimilar Met Primary Endpoints in Trial
19 Septiembre 2022 - 01:06AM
Noticias Dow Jones
By Joshua Kirby
Novartis AG said Monday that an integrated trial of denosumab, a
proposed biosimilar developed by its subsidiary Sandoz, generated
positive results.
Denosumab is indicated for the treatment of various conditions
including osteoporosis.
An integrated Phase 1-3 study of the biosimilar met its primary
endpoints of matching reference medicines and contributing to
demonstration of similarity, the Swiss drugmaker said.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
September 19, 2022 01:51 ET (05:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Nov 2023 a Dic 2023
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Dic 2022 a Dic 2023
